Literature DB >> 2453008

Intrapleural natural beta interferon in the treatment of malignant pleural effusions.

R Rosso1, R Rimoldi, F Salvati, M De Palma, A Cinquegrana, G Nicolò, A Ardizzoni, U Fusco, A Capaccio, R Centofanti.   

Abstract

Effusion recurrence is a major problem in the palliative care of patients with disseminated cancer. Thirty-two patients with recurrent malignant pleural effusions were treated with intracavitary natural beta-interferon at increasing doses (5-20 million units) for a maximum of three administrations. Among 29 evaluable patients, 11 showed complete (27.6%) or partial (10.3%) remission. No difference in response rate was observed according to sex, age, and histological type. All the responses were observed in patients with an effusion volume less than 1,000 ml (11/16; 68.8%). No side effect was observed. In conclusion, intrapleural beta-interferon is promising as a palliative in the treatment of recurrent malignant effusions.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2453008     DOI: 10.1159/000226571

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  7 in total

Review 1.  Management of lung cancer.

Authors:  A Melville; A Eastwood
Journal:  Qual Health Care       Date:  1998-09

2.  BTS guidelines for the management of malignant pleural effusions.

Authors:  G Antunes; E Neville; J Duffy; N Ali
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

Review 3.  Management of malignant pleural effusions.

Authors:  M H Tattersall; M J Boyer
Journal:  Thorax       Date:  1990-02       Impact factor: 9.139

Review 4.  Management of malignant pleural effusions.

Authors:  F Grossi; M C Pennucci; L Tixi; M A Cafferata; A Ardizzoni
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

5.  A phase I trial of intrapleural recombinant human interferon alpha (rHuIFN alpha 2b) in patients with malignant pleural effusions.

Authors:  A Bhatia; T W Rice; D McLain; P Herzog; G T Budd; S Murthy; T J Kirby; R M Bukowski
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

6.  Intrapleural Adenoviral-mediated Endothelial Cell Protein C Receptor Gene Transfer Suppresses the Progression of Malignant Pleural Mesothelioma in a Mouse Model.

Authors:  Shiva Keshava; L Vijaya Mohan Rao; Usha R Pendurthi
Journal:  Sci Rep       Date:  2016-11-11       Impact factor: 4.379

7.  Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.

Authors:  S H Goey; A M Eggermont; C J Punt; R Slingerland; J W Gratama; R Oosterom; R Oskam; R L Bolhuis; G Stoter
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.